Download Files:
GYKI 52466 (dihydrochloride)
$135 – $1,250
Products Details
Product Description
– GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson’s disease research[1][2].
Web ID
– HY-103234A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C17H17Cl2N3O2
References
– [1]S D Donevan, et al. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993 Jan;10(1):51-9.|[2]A G Chapman, et al. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 1991 Jul;9(2):92-6.
CAS Number
– 2319722-40-0
Molecular Weight
– 366.24
Compound Purity
– 99.38
SMILES
– NC1=CC=C(C2=NN=C(C)CC3=CC4=C(OCO4)C=C32)C=C1.[H]Cl.[H]Cl
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 2.78 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– iGluR
Isoform
– AMPA Receptor;Kainate Receptor
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
